Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
mitoxantrone hydrochloride liposome (CSPC Pharmaceutical Group, 9fc19e)
- Development stage
- Unknown
- Lead developer
- CSPC Pharmaceutical Group
- Modality
- Small Molecules, Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
Mitoxantrone hydrochloride liposome (PLM60) is a liposomal nano-formulation of the synthetic anthracycline-like agent mitoxantrone. It acts as a DNA topoisomerase II inhibitor, intercalating into DNA and causing strand breaks, which inhibits DNA synthesis and repair. This formulation is designed to improve the pharmacokinetic profile and reduce the cardiotoxicity associated with conventional mitoxantrone. It has been approved by China's National Medical Products Administration (NMPA) for the treatment of relapsed or refractory peripheral T-cell lymphoma. Additionally, it is being investigated in combination regimens, such as GVM±R (gemcitabine, vinorelbine, and mitoxantrone liposome with or without rituximab), for the treatment of relapsed or refractory aggressive non-Hodgkin's lymphoma.
- Brand names
- Duoenxi
- Other names
- liposomal mitoxantrone hydrochloridemitoxantrone liposome
02
Targets
DNATOP2B (DNA topoisomerase II beta)TOP2A (DNA topoisomerase II)
Beyond the preview
Go deeper on mitoxantrone hydrochloride liposome (CSPC Pharmaceutical Group, 9fc19e).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on mitoxantrone hydrochloride liposome (CSPC Pharmaceutical Group, 9fc19e).